Tags : Cluster

Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster

Vartika Singh June 5, 2019

Shots: The approval is based on Episodic Cluster Headache Study assessing Emgality (SC, 300 mg) vs PBO in 106 patients in ratio (1:1) with episodic cluster headache and had a […]readmore

Tags : Cluster

Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Cluster

﻿Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Eli Lilly’s Emgality (galcanezumab-gnlm) Receives FDA’s Approval for Episodic Cluster